Article
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Experimental hematology - 1 Apr 2014
Emadi Ashkan, Jun Sung Ah, Tsukamoto Takashi, Fathi Amir T, Minden Mark D, Dang Chi V
Abstract excerpt
The incidence of mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) in de novo acute myeloid leukemia (AML) is approximately 20%. These mutations result in distinct metabolic characteristics including dependency of cancer cells on glutamine as the main source for α-ketoglutarate, which is consumed by leukemia cells to produce a cancer-derived metabolite, 2-hydroxyglutarate. We sought to exploit this glutamine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.